Suppr超能文献

监管审查:各机构如何确保决策质量?

Regulatory review: How do agencies ensure the quality of decision making?

机构信息

Centre for Innovation in Regulatory Science, London, UK.

出版信息

Clin Pharmacol Ther. 2013 Sep;94(3):305-8. doi: 10.1038/clpt.2013.127.

Abstract

The Centre for Innovation in Regulatory Science (CIRS) Workshop on Regulatory Review brought together international regulators and multinational pharmaceutical company representatives to focus on best practices that underlie regulatory decision making, thereby facilitating the transparent, timely, procedurally predictable, and good-quality evaluation of new medicines. Participants investigated frameworks used by agencies, discussed challenges for regulatory agencies in making quality decisions, investigated the role of other stakeholders, and made recommendations of activities and processes that agencies and companies can consider to enable quality decision making.

摘要

监管科学创新中心(CIRS)监管审查研讨会召集了国际监管机构和跨国制药公司代表,重点讨论了监管决策所依据的最佳实践,从而促进了新药的透明、及时、程序上可预测和高质量的评估。参与者研究了各机构使用的框架,讨论了监管机构在做出质量决策方面面临的挑战,调查了其他利益相关者的作用,并就机构和公司可以考虑的活动和流程提出了建议,以促进质量决策。

相似文献

1
Regulatory review: How do agencies ensure the quality of decision making?
Clin Pharmacol Ther. 2013 Sep;94(3):305-8. doi: 10.1038/clpt.2013.127.
3
The innovative medicines initiative: a European response to the innovation challenge.
Clin Pharmacol Ther. 2012 Mar;91(3):418-25. doi: 10.1038/clpt.2011.321. Epub 2012 Feb 8.
4
Assessing the Quality of Decision Making in the Development and Regulatory Review of Medicines: Identifying Biases and Best Practices.
Ther Innov Regul Sci. 2017 Mar;51(2):250-256. doi: 10.1177/2168479016662681. Epub 2016 Sep 27.
5
The Confluence of Accelerated Regulatory and Health Technology Assessment Access Pathways.
Clin Pharmacol Ther. 2019 Apr;105(4):935-942. doi: 10.1002/cpt.1315. Epub 2019 Jan 16.
6
Quality of Regulatory Decision-Making Practices: Issues Facing Companies and Agencies.
Ther Innov Regul Sci. 2016 Jul;50(4):487-495. doi: 10.1177/2168479016628573.
7
Quality Decision-Making Practices in Pharmaceutical Companies and Regulatory Authorities: Current and Proposed Approaches to Its Documentation.
Ther Innov Regul Sci. 2020 Nov;54(6):1404-1415. doi: 10.1007/s43441-020-00167-7. Epub 2020 May 29.
8
Interaction initiatives between regulatory, health technology assessment and coverage bodies, and industry.
Int J Technol Assess Health Care. 2012 Oct;28(4):374-81. doi: 10.1017/S0266462312000591.
10
Is there a need for a universal benefit-risk assessment framework for medicines? Regulatory and industry perspectives.
Pharmacoepidemiol Drug Saf. 2013 Sep;22(9):1004-12. doi: 10.1002/pds.3464. Epub 2013 Jun 5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验